NCT03352323View on ClinicalTrials.gov

An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 18, 2017

Primary Completion Date

December 6, 2017

Study Completion Date

March 30, 2018

Conditions
RosaceaErythema
Interventions
DRUG

Oxymetazoline

RLD

Trial Locations (1)

77845

J&S Studies, College Station

Sponsors

Lead Sponsor

Padagis LLC
All Listed Sponsors
lead

Padagis LLC

INDUSTRY

NCT03352323 - An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea | Biotech Hunter | Biotech Hunter